Heart transplantation (HT) remains the definitive therapy for patients with end-stage heart failure (HF), significantly improving both survival and quality of life [1]. For this reason, meticulous post-transplant monitoring is essential to promptly detect complications such as acute cellular or antibody-mediated rejection, and to optimize immunosuppressive therapy accordingly. In this context, cardiac biomarkers have emerged as pivotal non-invasive tools for allograft surveillance, enabling early diagnosis and timely intervention, while potentially reducing the need for routine endomyocardial biopsies (EMB), the current gold standard, although invasive and subject to sampling error and interobserver variability [2, 3].